The mammalian target of rapamycin signalling network and gene regulation

Current Opinion in Lipidology

Volumn 16, Issue 3, 2005, Pages 317-323

  Soliman, Ghada A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

4EBP 1; Cell growth and proliferation; mTOR; S6K1; Tuberous sclerosis complex

Indexed keywords

ANTINEOPLASTIC AGENT; CAP BINDING PROTEIN; FATTY ACID; GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGENIC AGENT; RAPAMYCIN; RIBOSOME PROTEIN; S6 KINASE; TARGET OF RAPAMYCIN KINASE;

EMBRYO DEVELOPMENT; ENERGY; FUNGUS MUTANT; GENE CONTROL; GENE DELETION; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HOMOZYGOSITY; HUMAN; HYPERLIPIDEMIA; HYPOINSULINEMIA; KNOCKOUT MOUSE; METABOLIC DISORDER; NONHUMAN; NUTRIENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SCIENTIFIC LITERATURE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSLATION INITIATION; YEAST;

MAMMALIA;

EID: 20544451118     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mol.0000169352.35642.06     Document Type: Review

References (57)

1. Heitman J, Movva NR, Hall MN. Targets of cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991; 253:905-909.
2. Keith CT, Schreiber SL. PIK-related kinases; DNA repair, recombination and cell cycle checkpoints. Science 1995; 270:50-51.
3. Lorberg A, Hall MN. TOR: the first 10 years. Curr Top Microbiol Immunol 2004; 279:1-18. This review reveals the advances in the target of rapamycin research since the discovery of yeast TOR.
4. Brown E, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369:756-758.
5. Sabatini DM, Erjument-Bromage H, Lui M, et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78:815-822.
6. Cruz MC, Cavallo LM, Gorlach JM, et al. Rapamycin antifungal action is mediated via conserved complexes with FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Mol Cell Biol 1999; 6:4101-4112.
7. Bateman JM, McNeill H. Temporal control of differentiation by the insulin receptor/tor pathway in Drosophila. Cell 2004; 119:87-96.
8. Weisman R, Roitburg I, Nahari T, et al. Regulation of leucine uptake by tori + in Schizosaccharomyces pombe is sensitive to rapamycin. Genetics 2004; September 30 (e publication).
9. Jia K, Chen D, Riddle DL. The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development 2004; 131:3897-3906.
10. Menand B, Desnos T, Nussaume L, et al. Expression and disruption of the Arabidopsis TOR (target of rapamycin) gene. Proc Natl Acad Sci U S A 2002; 99:6422-6427.
11. Muni NI, Gross TP. Problems with drug-eluting coronary stents - the FDA perspective. N Engl J Med 2004; 351:1593-1595.
12. Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43:1170-1180.
13. Sabers CJ, Martin MM, Brunn GJ, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995; 270:815-822.
14. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23:3151 -3171. This review summarized current advances in mTOR research, with specific emphasis on the role of mTOR in cell growth (cell mass and size) and cell proliferation as the cells progress through the cell cycle.
15. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-1945. This overview article highlights the mTOR-dependent signaling pathways, mTOR upstream regulators and downstream effectors.
16. Fingar DC, Salama S, Tsou C, et al. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 2002; 16:1472-1487.
17. Murakami M, Ichisaka T, Maeda M, et al. mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol 2004; 24:6710-6718. The first report to confirm that disruption of the mTOR gene via targeting the kinase domain results in embryonic lethality.
18. Gangloff YG, Mueller M, Dann SG, et al. Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol 2004; 24:9508-9516. This study showed that targeted disruption of the mTOR gene after the deletion of exon 1 through exon 5 of mTOR is embryonically lethal at day E5.5.
19. Corradetti MN, Inoki K, Bardeesy N, et al. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 2004; 18:1533-1538.
20. Manning BD, Cantley LC. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci 2003; 28:573-576.
21. Li Y, Corradetti MN, Inoki K, et al. TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci 2004; 29:32-38. An excellent review summarizes the recent discovery of TSC-1/2 and its GTPase-activating protein activity against Rheb, thus antagonizing mTOR-dependent signaling.
22. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004; 6:91-99. This report provides a link between LKB1, AMPK, the TSC complex and mTOR signaling.
23. Jaeschke A, Dennis PB, Thomas G. mTOR: a mediator of intracellular homeostasis. Curr Top Microbiol Immunol 2004; 279:283-298. This article provides an overview of the regulation of mTOR-dependent signaling by amino acids and intracellular ATP levels.
24. Meijer AJ, Dubbelhuis PF. Amino acid signalling and the integration of metabolism. Biochem Biophys Res Commun 2004; 313:397-403.
25. Proud CG. mTOR-mediated regulation of translation factors by amino acids. Biochem Biophys Res Commun 2004; 313:429-436.
26. Kimball SR, Shantz LM, Horetsky RL, et al. Leucine regulates translation of specific mRNAs in L6 myoblasts through mTOR-mediated changes in availability of evIF4E and phosphorylation of ribosomal protein S6. J Biol Chem 1999; 274:11647-11652.
27. Kimball SR, Jefferson LS. Molecular mechanisms through which amino acids mediate signaling through the mammalian target of rapamycin. Curr Opin Clin Nutr Metab Care 2004; 7:39-44.
28. Tokunaga C, Yoshino K, Yonezawa K. mTOR integrates amino acid- and energy-sensing pathways. Biochem Biophys Res Commun 2004; 313:443-446. This review recaps the recent updates in mTOR-dependent regulation by AMPK, energy sensing and amino acids and the possible role of mitochondrial dysfunction in the inhibition of the mTOR downstream target, S6K-1.
29. Kim DH, Sabatini DM. Raptor and mTOR: subunits of a nutrient-sensitive complex. Curr Top Microbiol Immunol 2004; 279:259-270.
30. Yonezawa K, Yoshino KI, Tokunaga C, et al. Kinase activities associated with mTOR. Curr Top Microbiol Immunol 2004; 279:271-282.
31. Dennis PB, Jaeschke A, Saitoh M, et al. Mammalian TOR: a homeostatic ATP sensor. Science 2001; 294:1102-1105.
32. Shah OJ, Wang Z, Hunter T. Inappropriate activation of the TSC/Rheb/ mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 2004; 14:1650-1656. This study links mTOR, its upstream regulators, and downstream targets to insulin resistance and the negative regulation of IRS.
33. Hinault C, Mothe-Satney I, Gautier N, et al. Amino acids and leucine allow insulin activation of the PKB/mTOR pathway in normal adipocytes treated with wortmannin and in adipocytes from db/db mice. FASEB J 2004; 18:1894-1896. This report suggests that in the adipocytes, amino acids and insulin interact to regulate mTOR-mediated signal transduction.
34. Um SH, Frigerio F, Watanabe M, et al. Absence of S6K1 protects against age-and diet-induced obesity while enhancing insulin sensitivity. Nature 2004; 431:200-205.
35. Erratum in: Nature 2004; 431:485. This study is a follow-up on an initial observation that S6K1 knockout in mice leads to hypoinsulinemia and glucose intolerance. This report shows that S6K1 may play an important role in high fat diet-induced obesity.
36. Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004; 167:399-403. This review recapitulates a current overview of mTOR-dependent signaling and feedback inhibition of the insulin receptor substrate, and thereby its contribution to insulin resistance, obesity and cancer.
37. Aguirre V, Werner ED, Giraud J, et al. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 2002; 277:1531-1537.
38. Carlson CJ, White MF, Rondinone CM. Mammalian target of rapamycin regulates IRS-1 serine 307 phosphorylation. Biochem Biophys Res Commun 2004; 316:533-539. This study provides evidence that mTOR mediates the phosphorylation of IRS on the serine 307 residue.
39. Kim JE, Chen J. Regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 2004; 53:2748-2756. This report indicates that mTOR regulates adipogenesis by the regulation of transcription factors PPARγ and CCAAT/enhancer-binding protein α expression as well as PPARγ transactivation of downstream targets.
40. Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 2004; 166:213-223.
41. Fang Y, Vilella-Bach M, Bachmann R, et al. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001; 294:1942-1945.
42. Kim DH, Sarbassov dos D, Ali SM, et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 2003; 11:895-904. This report characterizes GβL as a modulator of mTOR kinase that stabilizes the interactions between mTOR and raptor.
43. Richardson CJ, Schalm SS, Blenis J. PI3-kinase and TOR: PIKTORing cell growth. Semin Cell Dev Biol 2004; 15:147-159.
44. Oshiro N, Yoshino K, Hidayat S, et al. Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function. Genes Cells 2004; 9:359-366. This study provides further evidence that rapamycin interferes with the stability of mTOR and raptor associations in vivo.
45. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6:1122-1128. This study reports the presence of the TOR complex 2 in addition to the existence of the TOR complex 1 in mammalian mTOR in a rapamycin-insensitive manner analogous to budding yeasts.
46. Sarbassov dos D, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14:1296-1302. This research is the first report to identify rictor as a rapamycin-insensitive partner of mTOR complex in a manner analogous to yeast TOR and AVO3 (adheres voraciously to TOR), formerly known as Tsc11, interactions.
47. Kim JE, Chen J. Cytoplasmic-nuclear shuttling of FKBP12-rapamycin- associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc Natl Acad Sci U S A 2000; 97:14340-14345.
48. Peng T, Golub TR, Sabatini DM. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol 2002; 22:5575-5584.
49. James MJ, Zomerdijk JC. Phosphatidylinositol 3-kinase and mTOR signaling pathways regulate RNA polymerase I transcription in response to IGF-1 and nutrients. J Biol Chem 2004; 279:8911 -8918.
50. Hannan KM, Brandenburger Y, Jenkins A, et al. mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol Cell Biol 2003; 23:8862-8877. This report identifies transcription factor UBF as an mTOR-dependent phosphorylation target.
51. Mayer C, Zhao J, Yuan X, et al. mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. Genes Dev 2004; 18:423-434. This study shows that mTOR regulates the transcriptional activation of transcription factor TIF-IA, thereby modulating polymerase I transcription.
52. Castedo M, Ferri KF, Blanco J, et al. Human immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/FKBP12-rapamycin-associated protein-mediated p53 phosphorylation. J Exp Med 2001; 194:1097-1110.
53. Hleb M, Murphy S, Wagner EF, et al. Evidence for cyclin D3 as a novel target of rapamycin in human T lymphocytes. J Biol Chem 2004; 279:31948-31935.
54. Yokogami K, Wakisaka S, Avruch J, et al. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 2000; 10:47-50.
55. Abraham RT. mTOR as a positive regulator of tumor cell responses to hypoxia. Curr Top Microbiol Immunol 2004; 279:299-319.
56. Parekh D, Ziegler W, Yonezawa K, et al. Mammalian TOR controls one of two kinase pathways acting upon nPKCdelta and nPKCepsilon. J Biol Chem 1999; 274:34758-34764.
57. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004; 10:594-601.